A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

被引:128
|
作者
Clark, WM
Wechsler, LR
Sabounjian, LA
Schwiderski, UE
机构
[1] Oregon Hlth Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA
[2] Univ Pittsburgh, Med Ctr, Stroke Inst, Pittsburgh, PA USA
[3] Interneuron Pharmaceut Inc, Lexington, MA USA
关键词
D O I
10.1212/WNL.57.9.1595
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Citicoline may reduce CNS ischemic injury by stabilizing cell membranes and reducing free radical generation. Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects. Objective: To determine the safety and efficacy of citicoline treatment in acute stroke patients. Methods: An 118-center, randomized, double-blind, efficacy trial in 899 patients compared placebo (n = 446) with citicoline (n = 453) (1000 mg PO twice a day) for 6 weeks, with a 6-week post-treatment follow-up period. Patients with acute (less than or equal to 24 hours) ischemic strokes clinically thought to be in the middle cerebral artery territory with NIH Stroke Scale (NIHSS) scores greater than or equal to8 were enrolled. Results: Mean time to treatment was 13 hours for both groups and mean age was 67 years for those receiving placebo and 68 years for those receiving citicoline. Mean baseline NIHSS scores were 14.5 for placebo and 13.9 for citicoline (p = 0.06); medians were 14 for placebo and 13 for citicoline (p = 0.04). The incidence and type of side effects were similar between the groups. There were no between-group differences on the planned primary analysis, percent of patients with a greater than or equal to7-point NIHSS score change at 90 days (placebo 51%, citicoline 52%). There were no between-group differences on the other planned secondary analyses at 90 days, including mortality. However, post hoc analyses using standard "excellent recovery" measures suggested a possible treatment effect on the modified Rankin 0 or 1 (last observation carried forward: placebo 20%, citicoline 26%; p = 0.025) as well as a global outcome statistic. Conclusions: Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses. Post hoc analyses suggest that a modest treatment effect may have been seen if more traditional analyses had been used.
引用
收藏
页码:1595 / 1602
页数:8
相关论文
共 50 条
  • [41] Remote Ischemic Perconditioning as an Adjunct Therapy to Thrombolysis in Patients With Acute Ischemic Stroke A Randomized Trial
    Hougaard, Kristina Dupont
    Hjort, Niels
    Zeidler, Dora
    Sorensen, Leif
    Norgaard, Anne
    Hansen, Troels Martin
    von Weitzel-Mudersbach, Paul
    Simonsen, Claus Z.
    Damgaard, Dorte
    Gottrup, Hanne
    Svendsen, Kristina
    Rasmussen, Peter Vestergaard
    Ribe, Lars R.
    Mikkelsen, Irene K.
    Nagenthiraja, Kartheban
    Cho, Tae-Hee
    Redington, Andrew N.
    Botker, Hans Erik
    Ostergaard, Leif
    Mouridsen, Kim
    Andersen, Grethe
    STROKE, 2014, 45 (01) : 159 - 167
  • [42] A randomized controlled trial of ligustrazine for acute ischemic stroke
    Bo, W
    Ming, L
    Song, T
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S415 - S415
  • [43] A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
    Berkhemer, O. A.
    Fransen, P. S. S.
    Beumer, D.
    van den Berg, L. A.
    Lingsma, H. F.
    Yoo, A. J.
    Schonewille, W. J.
    Vos, J. A.
    Nederkoorn, P. J.
    Wermer, M. J. H.
    van Walderveen, M. A. A.
    Staals, J.
    Hofmeijer, J.
    van Oostayen, J. A.
    Nijeholt, G. J. Lycklama A.
    Boiten, J.
    Brouwer, P. A.
    Emmer, B. J.
    de Bruijn, S. F.
    van Dijk, L. C.
    Kappelle, L. J.
    Lo, R. H.
    Van Dijk, E. J.
    de Vries, J.
    de Kort, P. L. M.
    van Rooij, W. J. J.
    van den Berg, J. S. P.
    van Hasselt, B. A. A. M.
    Aerden, L. A. M.
    Dallinga, R. J.
    Visser, M. C.
    Bot, J. C. J.
    Vroomen, P. C.
    Eshghi, O.
    Schreuder, T. H. C. M. L.
    Heijboer, R. J. J.
    Keizer, K.
    Tielbeek, A. V.
    den Hertog, H. M.
    Gerrits, D. G.
    van den Berg-Vos, R. M.
    Karas, G. B.
    Steyerberg, E. W.
    Flach, H. Z.
    Marquering, H. A.
    Sprengers, M. E. S.
    Jenniskens, S. F. M.
    Beenen, L. F. M.
    van den Berg, R.
    Koudstaal, P. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (01): : 11 - 20
  • [44] HEMODILUTION IN ACUTE ISCHEMIC STROKE - A RANDOMIZED MULTICENTER TRIAL
    ASPLUND, K
    STROKE, 1986, 17 (01) : 143 - 143
  • [45] ECCO 2000 study of citicoline for treatment of acute ischemic stroke: Effects on infarct volumes measured by MRI
    Warach, SJ
    Sabounjian, LAA
    STROKE, 2000, 31 (01) : 283 - 283
  • [46] Dodecafluropentane Emulsion in Acute Ischemic Stroke, a Phase One Randomized and Controlled Trial.
    Culp, William C.
    Onteddu, Sanjeeva
    Brown, Aliza
    Nalleballe, Krishna
    Sharma, Rohan
    Skinner, Robert
    Witt, Taylor
    Marsh, James
    STROKE, 2019, 50
  • [47] Neuroprotective therapy with citicoline (Ceraxon) in patients with ischemic stroke
    Martynov M.Y.
    Boiko A.N.
    Kamchatnov P.R.
    Kabanov A.A.
    Yasamanova A.N.
    Shchukin I.A.
    Kolesnikova T.I.
    Chubykin V.I.
    Glukhareva A.P.
    Gusev E.I.
    Neuroscience and Behavioral Physiology, 2013, 43 (6) : 706 - 711
  • [48] Citicoline in hypoxic ischemic encephalopathy in neonates: a randomized controlled trial
    Abeer Salamah
    Doaa El Amrousy
    Mai Elsheikh
    Mostafa Mehrez
    Italian Journal of Pediatrics, 49
  • [49] PHARMACOECONOMIC BENEFITS OF CITICOLINE IN THE TREATMENT OF ACUTE ISCHEMIC STROKE IN RUSSIA
    Ryazhenov, V. V.
    Gorokhova, S. G.
    VALUE IN HEALTH, 2013, 16 (07) : A519 - A520
  • [50] Citicoline in hypoxic ischemic encephalopathy in neonates: a randomized controlled trial
    Salamah, Abeer
    El Amrousy, Doaa
    Elsheikh, Mai
    Mehrez, Mostafa
    ITALIAN JOURNAL OF PEDIATRICS, 2023, 49 (01)